Status
Not yet recruiting
Phase
Phase 4
Enrollment
144
Locations
0
Results
Not posted
Publications
6
Study summary
The PPOS protocol (Progestin-primed Ovarian Stimulation) involves avoiding ovulation during ovarian stimulation with progesterone. It is a reliable and safe protocol that has been widely used in recent years for in vitro fertilization, as it reduces the number of injections needed during controlled ovarian stimulation and is more cost-effective for patients. The aim of this study is to compare two methods of ovarian stimulation for in vitro fertilization: the PPOS protocol (Group A) and the conventional protocol with injected antagonists (Group B). The goal is to determine whether both methods are equally effective in obtaining euploid embryos in the context of double ovarian stimulation.
Hypothesis: Hypothesis: The number of euploid embryos obtained in a DUOSTIM cycle with PPOS is not inferior to that obtained with the use of antagonists. General and Specific Objectives Main Objective: To study if there is a difference in the number of euploid embryos obtained in two groups of patients undergoing embryo accumulation for PGT-A through double ovarian stimulation, comparing two methods of pituitary suppression: Progesterone use from the start of stimulation and the use of GnRH antagonists. Secondary Objectives: Evaluate if there are differences between both groups regarding the number of MII oocytes. Evaluate if there are differences between both groups regarding the number of cumulus-oocyte complexes (COC). Study the differences between both groups regarding the total consumption of gonadotropins. Evaluate if there are differences between both groups regarding the number of stimulation days. Evaluate if there are differences in fertilization rate after microinjection. Evaluate if there are differences between both groups regarding the cancellation rate. Evaluate if there are differences between both groups regarding the number of total embryos. Evaluate if there are differences between both groups regarding the number of embryos subjected to trophectoderm biopsy.
Interventions
DRUG
Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).
DRUG
Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
Timeline
First posted
Oct 15, 2024
Study start
Oct 15, 2024
Primary completion
Jun 15, 2025
Study completion
Dec 31, 2025
Results posted
Not reported
Registry updated
Oct 15, 2024
Outcomes
Number of Euploid Embryos
Time frame · From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of euploid embryos after the two egg retrievals
Number of Oocytes retrieved
Time frame · From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of oocytes retrieved after the two egg retrievals
Number of Metaphase II oovcytes
Time frame · From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of metaphase II oocytes retrieved after the two egg retrievals
Number of Fertilized Oovytes
Time frame · From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of fertilized oocytes after the two egg retrievals
Number of Blastocysts
Time frame · From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of blastocyst stage embryos after the two egg retrievals
Eligibility
Inclusion Criteria: * Regular menstrual cycles between 21 and 35 days, inclusive. * Indication of IVF with PGT-A. * Both ovaries present. * Ability to participate and complete the study. * Give and sign the consent to participate in the study. Exclusion Criteria: * Endometriosis grade III/IV * Concurrent participation in another study
Study locations
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
Related trials
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
University of Delaware · Estrogen · Premenopause
Phase 4
Recruiting
30
2026-07
ART Fertility Clinics LLC · Healthy
Not applicable
Not yet recruiting
20
2026-05
Fundación Santiago Dexeus Font · Infertility
Phase 4
Completed
110
2026-04
Instituto Bernabeu · IVF
Phase 4
Completed
150
2026-03
Hanoi Medical University · Infertility (IVF Patients) · Embryo Morphokinetics
Not applicable
Recruiting
148
2026-02
University Hospital, Ghent · Ovarian Stimulation · Quality of Life
Phase 4
Recruiting
60
2025-12
Tam Anh TP. Ho Chi Minh General Hospital · Diminished Ovarian Reserve
Not applicable
Recruiting
730
2025-12
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.